Reuters: Regulatory News: Insmed's lung infection drug succeeds in late-stage trial

Changes are afoot at Blogtrottr! By popular request, we're bringing in paid plans with some cool new features (and more on the way). You can read all about it in our blog post.

Reuters: Regulatory News Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

Insmed's lung infection drug succeeds in late-stage trial Jul 1st 2013, 11:25 July 1 | Mon Jul 1, 2013 7:25am EDT July 1 (Reuters) - Insmed Inc said a late-stage trial of its experimental lung infection drug showed the therapy was as effective as another approved treatment. The drug, Arikace, was being tested as a treatment for a bacterial infection in cystic fibrosis patients. The trial met its main goal of showing Arikace was not inferior to Tovi, Novartis's drug for the same infection.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions